Phio Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 14, 2025 | Press Releases

Clinical trial advances for INSTASYL siRNA lead product candidate PH-7625th cohort enrolling patients in on-going clinical studyKing of Prussia, Pennsylvania–(Newsfile Corp. – August 14, 2025) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a...

Phio Pharmaceuticals Announces Exercise of Warrants for Approximately $2.5 Million Gross Proceeds

Jul 25, 2025 | Press Releases

King of Prussia, Pennsylvania–(Newsfile Corp. – July 25, 2025) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to...

Phio Pharmaceuticals Announces Pathology Results for Four of Five Patients in Fourth Cohort

Jul 25, 2025 | Press Releases

Complete Pathologic Response in patient with cutaneous squamous cell carcinoma Partial Response in Stage 4 metastatic Merkel cell patientKing of Prussia, Pennsylvania–(Newsfile Corp. – July 25, 2025) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a...

Phio Pharmaceuticals Announces Agreement with U.S. Manufacturing Source for Drug Substance

Jul 25, 2025 | Press Releases

Agreement covers contract development and manufacturing of lead compound PH-762King of Prussia, Pennsylvania–(Newsfile Corp. – July 25, 2025) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing...

Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Clinical Trial to Fifth Dose Escalation Cohort

Jun 25, 2025 | Press Releases

-Phio’s lead clinical siRNA compound PH-762 demonstrates supportive safety profile in fourth cohort, permitting dose escalation in expected final cohortMarlborough, Massachusetts–(June 25, 2025) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a...

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

Jun 24, 2025 | Press Releases

Registration Link for Presentation and live Q&A to take place, Monday, June 30, 2025 at 10:00 am ESTMarlborough, Massachusetts–(June 24, 2025) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing...